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Background: Primary ovarian insufficiency (POI) is characterized by 4 to 6 months of amenorrhea and elevated
serum FSH and LH in females less than 40 years. Ovarian insufficiency is uncommon in pediatrics and typically
results from a chromosomal abnormality or treatment for malignancy. Idiopathic POI in which no apparent
precipitant is identified is even rarer. After encountering three teens with idiopathic POI in recent months, we
utilized an informatics-enabled search of the electronic medical records from our hospital to identify all cases of
idiopathic POI presenting from 1998–2013.
Cases presentation: 15 girls (ages 14.4 to 17.9 years) met criteria for idiopathic POI. At diagnosis, breast
development ranged from Tanner stage 1 to 5; 6 of 15 patients had secondary amenorrhea. All patients presented
in the past 11 years and 13 of 15 in the past 5 years.
Conclusions: In this first case series of POI from the United States, we observed a clustering at our institution in
recent years. If an increased incidence of idiopathic POI is identified at other institutions, further investigation into
potential environmental and genetic precipitants is warranted.
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Primary ovarian insufficiency (POI) is characterized by 4
to 6 months of amenorrhea, persistently elevated serum
FSH and LH, and low serum estradiol in females
younger than 40 years [1]. POI occurs in an estimated
1/10,000 women before the age of 30 years but is un-
common during adolescence [2]. When POI occurs in
teens, it is typically iatrogenic (following oophorectomy
or treatment for malignancy) or due to a chromosomal
anomaly (Turner syndrome or Fragile X premutation)
[1]. Case series of idiopathic POI in pediatrics have been
reported from Italy [3] and Australia [4] involving 20
and 17 teens respectively between 1993 and 2006. To
our knowledge, no series of idiopathic POI in adoles-
cents has been reported in the United States.
We launched an informatics-enabled review of all
medical records to determine the number and clinical
presentation of teens with idiopathic POI. The review
was approved by the Stanford University Institutional* Correspondence: lkbach@stanford.edu
2Department of Pediatrics, Stanford University School of Medicine, Stanford,
CA, USA
Full list of author information is available at the end of the article
© 2015 Pederson et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Review Board. The Stanford Translational Research Inte-
grated Database Environment (STRIDE) patient cohort
discovery tool provided us with the means to search all
electronic medical records (EMR) between 1998 and
2013 [5]. Search criteria included age less than 19 years
and ICD-9 diagnosis codes of 256.9 (unspecified ovarian
dysfunction), 256.39 (other ovarian failure), 256.2 (post
ablative ovarian failure) or 256.31 (premature menopause).
Data extracted from the EMR included ICD-9 diagnoses,
laboratory, pathology and radiology reports, clinical notes,
pharmacy data, race, gender, zip code of residence and age
at diagnoses.Cases presentation
The STRIDE search identified 136 patients; clinical notes
were available for all but one. We reviewed these records
to identify cases of idiopathic POI using the inclusion
criteria of serum FSH and LH in the menopausal range,
low or undetectable estradiol, normal 46,XX karyotype,
and non-contributory past medical history. We excluded
patients with a history of oophorectomy, chemotherapy,
radiation or transplant [1].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cause (post malignancy, transplantation, or oophorec-
tomy) or genetic mutation (Turner syndrome, fragile X
permutation) leading to ovarian insufficiency (Table 1).
Some had disorders not associated with ovarian in-
sufficiency such as polycystic ovarian syndrome (PCOS),
eating disorders or exercise associated amenorrhea, indi-
cating an error in coding.
Fifteen females, ages 14.4 to 17.9 years, met our cri-
teria for idiopathic POI (Table 2). All had repeated la-
boratory measurements showing elevated gonadotropins
and a normal 46,XX karyotype. None had a history of
illness, medication, or radiation to account for ovarian
dysfunction. The 15 females presented between 2002
and 2013, and 13 of the 15 had been diagnosed since
2008. Heights, weights and BMI were largely normal.
While 9 of the girls had primary amenorrhea, only 3
lacked all secondary sexual characteristics. Comor-
bidities included hypothyroidism (n = 1), depression with
suicidal ideation (n = 2), IgA deficiency (n = 1), type 1
diabetes (n = 1) and tension headaches (n = 1). None of
the patients reported a family history of ovarianTable 1 Diagnoses for 136 subjects from STRIDE search
Diagnosis Number % of total




Turner syndrome 25 18
Organ transplant recipient 4 3
Galactosemia 2 1
Fragile X premutation 1 <1
Post-oophorectomy 4 3
Hypogonadotropic hypogonadism 27 20
CNS tumor = 8
Idiopathic = 5
Prader Willi syndrome = 1
Delayed puberty = 7
Exercise associated amenorrhea = 2
Eating disorder = 3
Depression = 1
Other 14 10
Polycystic ovarian syndrome = 2
Morbid obesity = 2
Irregular menses = 4
Wegener’s granulomatosis = 1
20p12.1 deletion = 1
46,XY males (CAH, androgen insensitivity,
gonadal dysgenesis) = 4
Incomplete clinical notes 1 <1insufficiency. No medications or environmental exposures
were common to all. All females resided in Northern or
Central California with no obvious zip code linkage.
Laboratory tests for autoimmunity were variably per-
formed but negative in most subjects: none of 12 tested
had adrenal antibodies and none of 7 had ovarian anti-
bodies. Three of 10 patients tested had positive anti-
thyroid peroxidase (TPO) antibodies but all 3 had normal
thyroid function tests. None of 7 patients assessed had
Fragile X premutations. None of 8 tested had detectable
anti-Mullerian hormone.
Pelvic imaging by trans-abdominal ultrasound was
performed on 10 females prior to estrogen therapy. This
imaging failed to detect ovaries in 4 girls and a uterus in
2 of these 4. MRI was conducted for 3 of these 4 pa-
tients and also failed to identify the reportedly absent
structures. Only one of these girls had Tanner 1 breasts.
After starting estrogen replacement therapy, all of these
patients had menstrual bleeding and were ultimately
found to have pelvic structures (uterus or ovaries) on
subsequent imaging.
Conclusions
In this first case series of idiopathic POI from the United
States, we identified 15 adolescents presenting since
1998 with 13 of 15 diagnosed in the past 5 years. Most
patients in our cohort had partial or complete secondary
sexual characteristics at presentation, and some had sec-
ondary amenorrhea. All warranted endocrine evaluation
because of absence of breast development by age 13,
lack of menses by age 15, or secondary amenorrhea [6].
The clinical presentation of idiopathic POI in these fe-
males was similar to that reported from Italy [4] and
Australia [5]. However, we found no family history sug-
gestive of genetic etiology. The Italian cohort included
one set of affected monozygotic twins and a non-twin
sister pair; another girl had a known family history of
premature ovarian failure [3]. The Australian cohort in-
cluded a girl with a family history of POI (4). We cannot
fully exclude a genetic cause in our cohort, however,
since we did not test for all genes linked to ovarian dys-
function on the X-chromosome and autosomes [7].
The majority of females in our cohort also lacked evi-
dence of autoimmunity. One had type 1 diabetes and
three had positive anti-TPO antibodies. Antibodies against
the 21-hydroxylase enzyme and ovary were negative in all
those who were tested. In the Italian series, 2 of the 20
girls had thyroid autoantibodies and 1 of these had clinical
evidence of thyroiditis, celiac disease and rheumatoid
arthritis [4]. One girl from the Australian series had
positive thyroid antibodies and 7 of 17 had positive anti-
nuclear antibodies [5]. Anti-ovarian and anti-adrenal anti-
bodies were negative in all subjects in both the Italian and
Australian series.
Table 2 Laboratory findings in POI cohort
Subject number Year of
diagnosis














1 2013 14.4 AI −0.2 −2.6 1 Primary 60.0 12.3 <1.0
2 2013 15.1 NHW −1.6 0.5 1 Primary 129.2 48.3 23.9
3 2013 16.4 NHW 1.4 −0.3 5 Primary 95.6 35.3 15.0
4 2012 15.1 AI −0.3 0.1 5 Primary 18.7 34.3 8.0
5 2012 15.2 NHW −1.7 −1.1 1 Primary 132.0 38.0 <1.0
6 2012 15.1 NHW 0.1 0.7 5 Primary 144.0 37.0 15.0
7 2012 15.2 Unknown 0 1.2 5 Secondary 74.6 28.5 <20
8 2011 17.2 Hispanic 1.2 −0.6 5 Secondary 77.9 31.4 <1.0
9 2010 16.4 Hispanic 1.1 0.9 5 Secondary 72.5 40.7 1.6
10 2009 17.1 Hispanic 0.8 −1.4 5 Secondary 106.0 51.0 18.0
11 2009 16.1 NHW 0.7 2.2 5 Secondary 48.0 23.0 <1.0
12 2008 15.3 AI 1.9 0.1 3 Primary 50.0 26.1 13.0
13 2008 17.9 AI 0.2 −0.5 5 Secondary 89.1 57.8 3.9
14 2006 17.1 Unknown 0.6 1.3 4 Primary 41.0 25.0 0.5
15 2002 16.1 Hispanic 0.5 −0.9 3 Primary 89.9 34.9 10.0
aAI = Asian -Indian. NHW = Non-Hispanic White. Unknown = not listed in medical record.
bBreast sexual maturity rating.
cUpper limit of normal reported as 12.8 mIU/mL.
dUpper limit of normal reported as 12 mIU/mL.
eLower limit of detectable estradiol varied by commercial laboratory. Prepubertal normal range reported as 5–20 pg/mL.
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therapy failed to detect ovaries in 4 of 10 girls and uterus
in 2; only one of these girls had Tanner 1 breasts. We
suggest caution in concluding that a uterus or ovaries are
absent in females with untreated POI, since ovaries are
typically small if estrogen levels are prepubertal [8].
We recognize the limitations of these retrospective
data from a single center. The EMR search was limited
to the 15 year period for which STRIDE was available.
Measurements of antibodies, fragile X analysis and pel-
vic imaging were not performed in all patients, as would
be recommended for optimal evaluation. We could not
definitively exclude changes in referral patterns as a con-
tributing factor to the apparent increase in idiopathic
POI cases in recent years. Adolescent Gynecology ser-
vices were established only in 2007. However, all but two
patients were initially referred by pediatricians to the
Pediatric Endocrine division which has been seeing pa-
tients for more than three decades. The other two were
referred by community endocrinologists. Because this
was a retrospective chart review, we were limited in our
ability to search for potential environmental exposures.
We utilized zip codes as a rough proxy for this variable
and found no clustering of cases.
Despite these limitations, we believe this case series
of idiopathic POI has important clinical and research
implications. Recognizing POI in teens who present
with amenorrhea is essential in order to provideappropriate endocrine, gynecologic, and reproductive
care and counseling [1,2]. If primary ovarian dysfunction
is confirmed by repeated elevations in FSH and LH, a
comprehensive work-up is indicated to determine the
cause [1]. We will now be monitoring for idiopathic POI
at our institution on a prospective basis to determine if
more cases arise. In fact, two more teens have presented
with this diagnosis since completion of the STRIDE
search. We are hoping other institutions will determine if
they are diagnosing idiopathic POI more frequently as
well. If this is the case, a search for environmental precipi-
tants and/or novel genetic causes is warranted.Consent
The study was approved by the Stanford University
Institutional Review Board. No individual written con-
sent was required for the STRIDE search. A copy of the
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Abbreviations
POI: Primary ovarian insufficiency; FSH: Follicle stimulating hormone;
LH: Luteinizing hormone; STRIDE: Stanford translational research integrated
database environment; MRI: Magnetic resonance imaging; PCOS: Polycystic
ovarian syndrome; AI: Asian Indian; NHW: Non-Hispanic white; BMI: Body
mass index; SMR: Sexual maturity rating; CNS: Central nervous system.
Competing interests
The authors declare that they have no competing interests.
Pederson et al. International Journal of Pediatric Endocrinology  (2015) 2015:13 Page 4 of 4Authors’ contributions
JP took primary responsibility for chart reviews, compiling clinical data and
scripting the first draft of this manuscript. This was completed while a
medical student in her final year. RBK constructed search criteria for the
STRIDE search, rechecked data in the medical record and contributed to editing
the manuscript. PH provided major editorial input on the manuscript with her
perspective and expertise as a pediatric gynecologist. LKB envisioned and
oversaw the entire project, served as mentor for JP, rechecked medical record
data, and revised the manuscript. All authors read and approved the final
manuscript.
Authors’ information
LKB has been in clinical practice of pediatric endocrinology since 1982.
She initiated this project after encountering three cases of POI in a four
month period after not having made this diagnosis for 20 years. The clinical
observation led to the initiative to systematically search for cases using the
STRIDE tool to scan all recent EMRs.
Acknowledgments
Dr. Pederson received funding from the Stanford Medical Scholars
Fellowship Program. We are grateful to Gomathi Krishnan, Ph.D. for
assistance with the STRIDE search. Support for STRIDE was provided by an
NIH Clinical and Translational Research Award UL1RR025744.
Author details
1Stanford University School of Medicine, Room H314, 300 Pasteur Drive,
Stanford, CA, USA. 2Department of Pediatrics, Stanford University School of
Medicine, Stanford, CA, USA. 3Department of Obstetrics and Gynecology,
Stanford University School of Medicine, Stanford, CA, USA.
Received: 23 December 2014 Accepted: 6 March 2015
References
1. Nelson L. Clinical Practice. Primary ovarian insufficiency. N Engl J Med.
2009;360:606–14.
2. Baker V. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet
Gynecol. 2013;25:375–81.
3. Arrigo T, Bertelloni S, Carcione L, De Luca F, De Sanctis C, Einaudi S, et al.
Characterization of Early Presentation Idiopathic Ovarian Failure in Girls and
Adolescents. J Pediatr Endocrinol Metab. 2003;16:835–42.
4. Cameron M, Grover S, Moore P, Jayasinghe Y. Non-Chromosomal,
Non-Iatrogenic Premature Ovarian Failure in an Adolescent Population:
A Case Series. J Pediatr Adolesc Gynecol. 2008;21:3–8.
5. Lowe HJ, Ferris TA, Hernandez PM, Weber SC. STRIDE – An integrated
standards-based translational research informatics platform. AMIA Ann Symp
Proc. 2009;2009:391–5.
6. American Academy of Pediatrics Committee on Adolescence, American
College of Obstetricians and Gynecologists, Committee on Adolescent
Health Care. Menstruation in girls and adolescents: Using the menstrual
cycle as a vital sign. Pediatrics. 2006;118:2245–50.
7. Cordts E, Christofiloni D. Genetic aspects of premature ovarian failure:
a literature review. Arch Gynecol Obstet. 2011;283:635–43.
8. Michala L, Aslam N, Conway GS, Creighton SM. The clandestine uterus: or
how the uterus escapes detection prior to puberty. BJOG. 2010;117:212–15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
